The Triangulation WIthin a STudy (TWIST) framework for causal inference within pharmacogenetic research.
Journal
PLoS genetics
ISSN: 1553-7404
Titre abrégé: PLoS Genet
Pays: United States
ID NLM: 101239074
Informations de publication
Date de publication:
09 2021
09 2021
Historique:
received:
28
04
2021
accepted:
17
08
2021
revised:
20
09
2021
pubmed:
9
9
2021
medline:
15
12
2021
entrez:
8
9
2021
Statut:
epublish
Résumé
In this paper we review the methodological underpinnings of the general pharmacogenetic approach for uncovering genetically-driven treatment effect heterogeneity. This typically utilises only individuals who are treated and relies on fairly strong baseline assumptions to estimate what we term the 'genetically moderated treatment effect' (GMTE). When these assumptions are seriously violated, we show that a robust but less efficient estimate of the GMTE that incorporates information on the population of untreated individuals can instead be used. In cases of partial violation, we clarify when Mendelian randomization and a modified confounder adjustment method can also yield consistent estimates for the GMTE. A decision framework is then described to decide when a particular estimation strategy is most appropriate and how specific estimators can be combined to further improve efficiency. Triangulation of evidence from different data sources, each with their inherent biases and limitations, is becoming a well established principle for strengthening causal analysis. We call our framework 'Triangulation WIthin a STudy' (TWIST)' in order to emphasise that an analysis in this spirit is also possible within a single data set, using causal estimates that are approximately uncorrelated, but reliant on different sets of assumptions. We illustrate these approaches by re-analysing primary-care-linked UK Biobank data relating to CYP2C19 genetic variants, Clopidogrel use and stroke risk, and data relating to APOE genetic variants, statin use and Coronary Artery Disease.
Identifiants
pubmed: 34495953
doi: 10.1371/journal.pgen.1009783
pii: PGENETICS-D-21-00581
pmc: PMC8452063
doi:
Substances chimiques
Cytochrome P-450 CYP2C19
EC 1.14.14.1
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
e1009783Subventions
Organisme : Medical Research Council
ID : MC_PC_17228
Pays : United Kingdom
Organisme : Medical Research Council
ID : MC_QA137853
Pays : United Kingdom
Organisme : NIA NIH HHS
ID : R21 AG060018
Pays : United States
Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
Int J Epidemiol. 2003 Feb;32(1):1-22
pubmed: 12689998
Nat Commun. 2014 Oct 28;5:5068
pubmed: 25350695
Int J Epidemiol. 2016 Dec 1;45(6):1866-1886
pubmed: 28108528
J Epidemiol Community Health. 2003 Jun;57(6):424-8
pubmed: 12775787
N Engl J Med. 2009 Jan 22;360(4):354-62
pubmed: 19106084
JAMA. 2016 Nov 1;316(17):1818-1819
pubmed: 27802529
Stat Methods Med Res. 2012 Feb;21(1):3-5
pubmed: 22250015
JAMA. 2011 Dec 28;306(24):2704-14
pubmed: 22203539
J Epidemiol Community Health. 2005 Sep;59(9):740-8
pubmed: 16100311
Stat Sci. 2010 Feb 1;25(1):1-21
pubmed: 20871802
Curr Protoc Hum Genet. 2017 Oct 18;95:1.22.1-1.22.23
pubmed: 29044472
PLoS Med. 2015 Mar 31;12(3):e1001779
pubmed: 25826379
Int J Epidemiol. 2018 Feb 1;47(1):226-235
pubmed: 29040562
Circulation. 2017 Jan 3;135(1):34-37
pubmed: 28028061
Hum Mol Genet. 2018 Aug 1;27(R2):R195-R208
pubmed: 29771313
Emerg Themes Epidemiol. 2019 Jan 7;16:1
pubmed: 30627207